Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2023-12-05 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 first extraordinary general meeting (临时股东大会) of Betta Pharmaceuticals Co., Ltd. It includes voting results for multiple proposals, attendance details, legal opinions, and compliance with relevant laws and regulations. The content focuses on the official results of shareholder votes at a general meeting, including percentages of votes for, against, and abstentions, as well as procedural compliance. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a presentation or a proxy solicitation but specifically the official announcement of voting results from a shareholders meeting. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters but contains substantive voting data, so it is not merely a report publication announcement or a regulatory filing. Confidence in this classification is high.
2023-12-05 Chinese
国浩律师（杭州）事务所关于贝达药业股份有限公司2023年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, agenda, and voting results of Betta Pharmaceuticals' 2023 First Extraordinary General Meeting (临时股东大会). It details the legality and validity of the meeting's call, attendance qualifications, agenda items, voting procedures, and results. The document is not a report of financial results, audit, or management discussion, but a legal opinion on the shareholder meeting process and outcomes. It is not a simple announcement but a detailed legal opinion letter. This type of document corresponds to Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides official results and legal validation of shareholder votes at a general meeting.
2023-12-05 Chinese
监事会关于公司2023年限制性股票激励计划激励对象名单的公示情况说明及核查意见
Regulatory Filings Classification · 95% confidence The document is a public announcement by the supervisory board regarding the list of incentive recipients under the company's 2023 restricted stock incentive plan. It includes details about the internal public notice, verification of the incentive recipients' qualifications, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial data, nor is it a report of financial results or management discussion. It is a regulatory announcement related to corporate governance and compliance with stock incentive regulations. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance disclosure rather than a financial report or management report.
2023-11-30 Chinese
中信证券股份有限公司关于贝达药业股份有限公司使用部分闲置募集资金暂时补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the use of part of idle raised funds by Betta Pharmaceuticals Co., Ltd. to temporarily supplement working capital. It references regulatory rules from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, discusses fundraising details, usage plans, board and supervisory approvals, independent director opinions, and the sponsor's verification opinion. The document is not a full financial report but a formal verification and compliance opinion related to the use of raised funds. It does not contain financial statements or earnings data but is a regulatory compliance and verification document. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-11-21 Chinese
贝达药业股份有限公司章程（2023年11月）
Governance Information Classification · 100% confidence The document is titled "贝达药业股份有限公司章程" which translates to "Betta Pharmaceuticals Co., Ltd. Articles of Association". It contains detailed chapters and sections about the company's general principles, business scope, shares issuance, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, party building, financial accounting system, profit distribution and audit, notices and announcements, mergers, splits, capital increases and decreases, dissolution and liquidation, amendments to the articles, and other provisions. The content is a comprehensive governance document outlining the company's internal rules, board structure, shareholder rights, meeting procedures, and other governance practices. It is not a financial report, earnings release, or announcement but a governance charter. Therefore, the appropriate classification is Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the articles, not a brief announcement or summary.
2023-11-17 Chinese
独立董事关于2023年限制性股票激励计划公开征集表决权的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement by the independent director of a company regarding the public solicitation of voting rights for proposals related to the 2023 restricted stock incentive plan to be considered at the 2023 first extraordinary general meeting. It details the solicitation process, voting intentions, and instructions for shareholders to authorize voting rights. The document does not contain financial statements or results but is focused on the solicitation of votes for specific proposals at a shareholder meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it pertains to the collection and announcement of voting rights for shareholder proposals.
2023-11-17 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.